Buy Amar Remedies on dips: Tater

Buy Amar Remedies on dips, says Ashish Tater, Fort Share Broking.

Tater told CNBC-TV18, "Amar Remedies is a buy on dip and good support around current levels. I think the company can achieve day target of close to Rs 97.50."
The company's trailing 12-month (TTM) EPS was at Rs 13.77 per share. (Dec, 2010). The stock's price-to-earnings (P/E) ratio was 6.88. The latest book value of the company is Rs 68.72 per share. At current value, the price-to-book value of the company was 1.38. The dividend yield of the company was 1.06%.